

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A process of preparing cells for cell therapy, comprising the steps of:

inducing helper T Th cells that have a nonspecific antitumor activity; and
imparting antigen specificity to the helper T Th cells

wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.

2. **(Cancelled)**

3. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the step of imparting antigen specificity to the helper T Th cells is carried out by transducing ~~a gene for~~ a class I-restricted T cell receptor gene TCR that recognizes a cancer-associated antigen.

4. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the step of imparting antigen specificity to the helper T Th cells is carried out by transducing ~~a gene for~~ a class II-restricted T cell receptor gene TCR that recognizes a cancer-associated antigen.

5. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 1, 3 or 4 ~~2-to-4~~, wherein the cancer-associated antigen is selected from the group consisting of Wilms' Tumor 1 WT1, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.
6. **(Withdrawn-Currently Amended)** The process for preparing cells for cell therapy according to claim 1, wherein the step of inducing helper T Th cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody and IL-2.
7. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 1, 3, 4 or 6 ~~1-to-6~~, further comprising a step of purifying the helper T Th cells to which antigen specificity has been imparted.
8. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 7, wherein the step of purifying the helper T Th cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.
9. **(Currently Amended)** A process of preparing cells for cell therapy, comprising the steps of:

inducing helper T 1 Th1 cells and cytotoxic T 1 Te1 cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T 1 Th1 cells and cytotoxic T 1 Te1 cells
wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is
carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.

10. **(Cancelled)**

11. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of imparting antigen specificity to the helper T 1 Th1 cells and cytotoxic T 1 Te1 cells is carried out by transducing ~~a gene for a class I-restricted T cell receptor gene TCR~~ that recognizes a cancer-associated antigen.

12. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of imparting antigen specificity to the helper T 1 Th1 cells and cytotoxic T 1 Te1 cells is carried out by transducing ~~a gene for a class II-restricted T cell receptor gene TCR~~ that recognizes a cancer-associated antigen.

13. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 9 to 12, 9, 11 or 12, wherein the cancer-associated antigen is selected from the group consisting of Wilms' Tumor 1 WT1, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1,

MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

14. **(Withdrawn-Currently Amended)** The process for preparing cells for cell therapy according to claim 9, wherein the step of inducing helper T 1 Th1 cells and cytotoxic T 1 Te1 cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody, IL-2, and IL-12.

15. **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 9, 11, 12 or 14, further comprising a step of separating the helper T 1 Th1 cells and cytotoxic T 1 Te1 cells to which antigen specificity has been imparted.

16. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 15, wherein the process of separating the helper T 1 Th1 cells and cytotoxic T 1 Te1 cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

17. **(Currently Amended)** The process for preparing cells for cell therapy according to claim 15-~~or 16~~, further comprising a step of mixing the separated helper T 1 Th1 cells and cytotoxic T 1 Te1 cells in any given proportion.

18. **(Withdrawn-Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper T Th cells that have a nonspecific antitumor activity; and
imparting antigen specificity to the helper T Th cells, wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.

19. **(Withdrawn-Currently Amended)** Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper T 1 Th1 cells and cytotoxic T 1 Te1 cells that have a nonspecific antitumor activity; and
imparting antigen specificity to the helper T 1 Th1 cells and cytotoxic T 1 Te1 cells, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.

20. **(Withdrawn-Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;
inducing from the leukocytes helper T Th cells that have a nonspecific antitumor activity;
imparting antigen specificity to the helper T Th cells, wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen; and

administering to the patient the helper T Th cells to which antigen specificity has been imparted.

21. **(Withdrawn-Currently Amended)** A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes helper T 1 Th1 cells and cytotoxic T 1 Te1 cells that have a nonspecific antitumor activity;

imparting antigen specificity to the helper T 1 Th1 cells and cytotoxic T 1 Te1 cells, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen; and

administering to the patient the helper T 1 Th1 cells and cytotoxic T 1 Te1 cells to which antigen specificity has been imparted.